Arcus Biosciences Q2 EPS $(1.04) Misses $(1.00) Estimate, Sales $29.00M Miss $35.86M Estimate
Portfolio Pulse from Benzinga Newsdesk
Arcus Biosciences reported Q2 losses of $(1.04) per share, missing the analyst consensus estimate of $(1.00) by 4 percent. This is an 11.83 percent decrease from the same period last year. The company also reported quarterly sales of $29.00 million, missing the analyst consensus estimate of $35.86 million by 19.13 percent. However, this is an 8.37 percent increase from the same period last year.
August 07, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Arcus Biosciences' Q2 earnings missed estimates, with a larger loss per share and lower sales than expected.
Arcus Biosciences reported a larger loss per share and lower sales than expected for Q2. This could negatively impact investor sentiment and potentially lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100